Skip to content
10-Q

Quarterly Report

AbbVie Inc. ABBV

0001551152-25-000029

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 1.77B sh
Short Term Debt Q1 2025 · Mar 31, 2025 $1.59B
Short Term Debt Q1 2025 · Dec 31, 2024 $0
Short Term Investments Q1 2025 · Mar 31, 2025 $1M
Short Term Investments Q1 2025 · Dec 31, 2024 $31M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $5.18B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $5.52B
Stockholders Equity Q1 2025 · Mar 31, 2025 $1.42B
Stockholders Equity Q1 2025 · Dec 31, 2024 $3.33B
Current Liabilities Q1 2025 · Mar 31, 2025 $36.4B
Current Liabilities Q1 2025 · Dec 31, 2024 $38.75B
Current Assets Q1 2025 · Mar 31, 2025 $27.68B
Current Assets Q1 2025 · Dec 31, 2024 $25.58B
Total Assets Q1 2025 · Mar 31, 2025 $136.17B
Total Assets Q1 2025 · Dec 31, 2024 $135.16B
Shares Diluted Q1 2025 · Mar 31, 2024 1.77B sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $1.32B
Dividends Paid Q1 2025 · Mar 31, 2024 $2.77B
Capex Q1 2025 · Mar 31, 2024 $193M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $4.04B
Eps Diluted Q1 2025 · Mar 31, 2024 $0.77
Eps Basic Q1 2025 · Mar 31, 2024 $0.77
Sga Expense Q1 2025 · Mar 31, 2024 $3.32B
Net Income Q1 2025 · Mar 31, 2024 $1.37B
Operating Income Q1 2025 · Mar 31, 2024 $2.8B
Cost Of Revenue Q1 2025 · Mar 31, 2024 $4.09B